BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.01 per share a year
Fourth quarter 2025  revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-year GAAP gross margin of 63% and non-GAAP
BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mar
BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market,
BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $2
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Campbell and CO Investment Adviser LLC raised its stake in shares of BioLife Solutions, Inc. (NASDAQ: BLFS) by 160.5% during the third quarter, according to the company in its most recent Form 13F fil
BioLife Solutions (NASDAQ: BLFS - Get Free Report) and Generation Alpha (OTCMKTS:GNAL - Get Free Report) are both medical companies, but which is the superior business? We will compare the two busines
Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter Full year unaudited revenue from continuing operations of $96.2 million ex
Envista (NYSE: NVST - Get Free Report) and BioLife Solutions (NASDAQ: BLFS - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based
Terumo (OTCMKTS:TRUMY - Get Free Report) and BioLife Solutions (NASDAQ: BLFS - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses base

BioLife Solutions' CFO Sells 30,000 Shares

08:03am, Thursday, 11'th Dec 2025
The CFO sold 30,000 shares for $771,600. This transaction represented 16.4% of Wichterman's direct holdings, reducing his direct stake to 152,769 shares.
Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in BioLife Solutions, Inc. (NASDAQ: BLFS) during the undefined quarter, according to its most recent disclosure wit
New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation BOTHELL, Wash. ,
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE